Screening for Medication-Related Functional Burden Before Complex Long-Term Regimens

Abstract

Medication-related functional burden (MRFB) is increasingly recognized as a critical factor impacting patient outcomes, particularly in populations managed with complex and long-term pharmacological regimens. Proactively screening for MRFB prior to the initiation of such therapies can identify individuals at heightened risk of adverse effects, functional decline, and non-adherence, thereby facilitating personalized interventions. This review synthesizes recent evidence and guidelines on the epidemiology, pathophysiology, risk factors, and clinical implications of MRFB, with a focus on optimizing management strategies for at-risk populations. Practical approaches to assessment, emerging tools, and future directions are discussed to equip clinicians with actionable insights for integrating MRFB screening into routine care.

Introduction

Polypharmacy and complex medication regimens are prevalent in modern clinical practice, especially among older adults and those with multimorbidity. While pharmacotherapy is essential for disease control, the cumulative functional impact of medications—referred to as medication-related functional burden—can significantly diminish quality of life, independence, and treatment adherence. Early identification and mitigation of MRFB are now recognized as crucial components of patient-centered care and medication optimization. This article delineates the epidemiological trends, mechanistic underpinnings, and clinical strategies for screening MRFB, drawing on recent guidelines and evidence to inform best practices.

Epidemiology / Disease Burden

MRFB is particularly prevalent among older adults, with studies reporting that up to 40-50% of community-dwelling seniors experience some degree of functional impairment attributable to medication use. The risk escalates with the number of prescribed agents, duration of therapy, and the presence of comorbidities, including cognitive impairment and frailty. Hospitalizations and emergency visits related to medication side effects or functional decline are common, underscoring the substantial healthcare burden associated with MRFB. Recent large-scale cohort studies highlight that MRFB is not limited to geriatrics but also affects patients with chronic illnesses such as heart failure, diabetes, and mental health disorders, where polypharmacy is frequent.

Pathophysiology

The mechanisms underlying MRFB are multifactorial and patient-specific. Pharmacodynamic and pharmacokinetic changes, particularly in older adults, amplify susceptibility to adverse drug reactions (ADRs) such as sedation, orthostatic hypotension, cognitive slowing, and impaired mobility. Drug-drug and drug-disease interactions can exacerbate baseline functional limitations, while medications with anticholinergic, sedative, or psychotropic properties are frequent culprits. Furthermore, medication-related fatigue, weakness, and falls often result from the cumulative effects of multiple agents, highlighting the importance of mechanistic awareness in clinical assessment.

Risk Factors

Key risk factors for MRFB include advanced age, polypharmacy (typically defined as five or more concurrent medications), preexisting cognitive or functional impairment, renal or hepatic dysfunction, and the use of high-risk medications (e.g., benzodiazepines, anticholinergics, opioids). Social determinants, such as poor health literacy, lack of caregiver support, and socioeconomic disadvantage, can further compound risk. Recent evidence emphasizes the importance of considering frailty status and multimorbidity clusters when assessing vulnerability to MRFB, as these factors independently predict poorer outcomes.

Clinical Features

Clinically, MRFB manifests as new or worsening difficulties in activities of daily living (ADLs), such as bathing, dressing, mobility, and feeding, as well as instrumental activities of daily living (IADLs) like medication management and financial tasks. Patients may present with non-specific complaints including fatigue, confusion, dizziness, or falls, often leading to under-recognition of medication-related causality. Subtle cognitive deficits, urinary incontinence, and reduced social engagement are also common presentations, necessitating a high index of suspicion among clinicians.

Diagnosis

Diagnosis of MRFB requires a systematic assessment that integrates medication review with functional status evaluation. Validated tools, such as the Medication-Related Burden Quality of Life (MRB-QoL) scale and the Drug Burden Index (DBI), can quantify the cumulative anticholinergic and sedative load. Comprehensive geriatric assessment (CGA) frameworks, which incorporate cognitive, physical, and psychosocial domains, are particularly effective for identifying patients at risk. Regular reconciliation of medication lists, including over-the-counter and complementary therapies, is essential to ensure accuracy. Collaboration with pharmacists and interdisciplinary teams enhances the detection and mitigation of MRFB.

Treatment & Management

Management strategies center on deprescribing unnecessary medications, substituting safer alternatives, and simplifying regimens where feasible. Individualized care plans, informed by patient preferences and goals, are foundational. Regular follow-up and monitoring for functional changes are critical to assess the impact of interventions. Non-pharmacological approaches, such as physical therapy and occupational therapy, can help restore or maintain function. Patient and caregiver education fosters adherence and empowers shared decision-making. In complex cases, referral to specialized geriatric or pharmacology services may be warranted.

Recent Advances / Emerging Therapies

Recent advances include the development of electronic health record (EHR)-integrated risk stratification tools that flag high-risk patients in real time. Mobile applications for self-monitoring and telehealth platforms facilitate remote assessment of functional status and medication effects. Artificial intelligence (AI)-driven algorithms are being explored to predict adverse outcomes based on medication profiles and patient characteristics. Emerging evidence supports the integration of MRFB screening into routine medication reviews, with pilot studies demonstrating improvements in functional outcomes and reduced healthcare utilization.

Guideline Recommendations

International guidelines, including those from the American Geriatrics Society (AGS) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), advocate for routine screening of medication-related functional impact in at-risk populations. Recommendations emphasize the use of validated assessment tools, interdisciplinary collaboration, and patient-centered approaches to medication management. Periodic re-evaluation is advised, especially following changes in therapy or clinical status. Incorporating MRFB assessment into quality metrics and clinical pathways is increasingly recognized as a marker of high-quality care.

Conclusion

Screening for medication-related functional burden prior to the initiation of complex long-term regimens represents a pivotal opportunity to optimize patient outcomes, reduce adverse events, and enhance quality of life. Early identification and proactive management of MRFB require a multidisciplinary, evidence-based approach that integrates functional assessment with pharmacological review. As the complexity of care continues to rise, embedding MRFB screening into standard clinical workflows will be essential for advancing patient safety and promoting individualized, high-value care.